|
Psychopharmacotherapy of Disruptive Behaviors in Intellectual and Developmental Disorders: Past, Present, and Future |
| Sunday, May 28, 2017 |
| 4:00 PM–4:50 PM |
| Convention Center Four Seasons Ballroom 1 |
| Area: DDA; Domain: Service Delivery |
| Instruction Level: Intermediate |
| CE Instructor: Eric Boelter, Ph.D. |
| Chair: Eric Boelter (Seattle Children's Autism Center) |
| BRYAN H. KING (Weill Institute for Neurosciences, University of California San Francisco) |
 Bryan H. King, MD, MBA, is Professor of Psychiatry and Vice Chair of Child and Adolescent Psychiatry for UCSF Health, as well as Vice President for Child Behavioral Health Services at UCSF Benioff Children’s Hospitals. A graduate of the Medical College of Wisconsin and the George Washington University School of Business, King has previously held faculty appointments at the UCLA David Geffen School of Medicine and Dartmouth Medical School. He has worked in a number of key clinical leadership positions at Seattle Children’s Hospital, the Dartmouth-Hitchcock Medical Center and Children’s Hospital at Dartmouth-Hitchcock, and the UCLA Neuropsychiatric Institute and Hospital, in addition to serving as medical director for State of New Hampshire’s Division of Developmental Services. Prior to joining UCSF, King was professor, vice chair, and director of child and adolescent psychiatry at the University of Washington, as well as chair of the Department of Psychiatry and Behavioral Health at Seattle Children’s Hospital. He also served as the founding director of the Seattle Children’s Autism Center. In these positions, he has overseen a significant expansion of psychiatric services for the children and families of Seattle and the State of Washington. King’s research has focused largely on psychopathology in intellectual and developmental disorders. He has authored more than 120 academic publications and has participated in several of the major multi-site medication trials in autism spectrum disorder. |
| Abstract: Although evidence has grown with respect to identifying pharmacological approaches to the treatment of severe disruptive behaviors, many challenges have limited progress to date. Few medications have FDA approved indications for the treatment of behavioral disturbance in the population with developmental disorders, and questions can be raised about their specificity. Problems with heterogeneity of study populations can challenge the ability to identify therapeutic signals as well as the generalizability of findings. This presentation will review the current evidence base for addressing common behavioral target symptoms and underscore the need for a change in the current path of drug development to a more integrated, biobehavioral approach. |
| Target Audience: Behavior Analysts, Psychologists, Psychiatrists |
| Learning Objectives: At the conclusion of the presentation, participants will be able to: (1) discuss common therapeutic targets in ASD and the evidence base for particular medications; (2) highlight challenges that have limited progress to date and the need for biobehavioral integration; (3) highlight emerging opportunities and future directions. |
|
| |